Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 4/20 | 0.46 |
| ▸ | NOS3 | P29474 | 3/20 | 0.46 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.42 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.42 |
| ▸ | DHFR | P00374 | 1/20 | 0.40 |
| ▸ | GALR3 | O60755 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | BACE1 | P56817 | 1/20 | 0.36 |
| ▸ | GFER | P55789 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9536189 | 0.84 | NOS2 (0.47) | NOS2NOS3ROCK1IDO1 | |
| SCHEMBL5218648 | 0.82 | MAOA (0.45) | ROCK1NR3C2DHFRKCNH2BACE1 | |
| SCHEMBL16919118 | 0.77 | HTT (0.51) | ROCK1CYP1A2NR3C2 | |
| SCHEMBL6031149 | 0.76 | NOS2 (0.53) | NOS2NOS3CYP1A2CYP2A6 | |
| SCHEMBL5216556 | 0.76 | BACE1 (0.42) | NOS2NOS3ROCK1NR3C2KCNH2 | |
| SCHEMBL27900729 | 0.73 | TLR8 (0.47) | NOS2NOS3 | |
| SCHEMBL27405845 | 0.72 | NOS2 (0.43) | NOS2NOS3BACE1 | |
| SCHEMBL6031561 | 0.71 | NOS2 (0.44) | NOS2NOS3 | |
| SCHEMBL30676176 | 0.71 | NOS2 (0.44) | NOS2NOS3 | |
| SCHEMBL28680564 | 0.71 | KCNH2 (0.46) | CYP1A2CYP2A6TAAR1DHFRKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1490366-B1 | ALKOXYPYRIDINE-DERIVATIVES | NYCOMED GMBH (DE) | 2008-01-23 | — | — | EP | disclosed |
| CN-1307176-C | Novel alkoxypyridine derivatives | ALTANA PHARMA AG (DE) | 2007-03-28 | — | — | CN | disclosed |
| US-7138399-B2 | 2-[2-(4-alkoxypyridin-2-yl)alkyl])-3H-imidazo[4,5-b]pyridine derivatives and 8-[2-(4-alkoxypyridin-2-yl)alkyl])-9H-purine derivatives; used to treat an acute inflammatory disease in which the activity of inducible NO-synthase is involved | ALTANA PHARMA AG (DE) | 2006-11-21 | — | — | US | disclosed |
| US-20050171125-A1 | 2-[2-(4-alkoxypyridin-2-yl)alkyl])-3H-imidazo[4,5-b]pyridine derivatives and 8-[2-(4-alkoxypyridin-2-yl)alkyl])-9H-purine derivatives; used to treat an acute inflammatory disease in which the activity of inducible NO-synthase is involved | ALTANA PHARMA AG (DE) | 2005-08-04 | — | — | US | disclosed |
| CN-1642955-A | Novel alkoxypyridine derivatives | ALTANA PHARMA AG (DE) | 2005-07-20 | — | — | CN | disclosed |
| EP-1490366-A1 | NOVEL ALKOXYPYRIDINE-DERIVATIVES | ALTANA Pharma AG (DE) | 2004-12-29 | — | — | EP | disclosed |
| WO-2003080607-A1 | NOVEL ALKOXYPYRIDINE-DERIVATIVES | ALTANA PHARMA AG (DE) | 2003-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171125-A1 | 2-[2-(4-alkoxypyridin-2-yl)alkyl])-3H-imidazo[4,5-b]pyridine derivatives and 8-[2-(4-alkoxypyridin-2-yl)alkyl])-9H-purine derivatives; used to treat an acute inflammatory disease in which the activity of inducible NO-synthase is involved | NOS2, PNP, PTGIS | NOS2 1/4885NOS3 6/4885ROCK1 1983/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.